The vaccines being distributed in the US and EU have both completed _three_ stages of trials run under quite strict conditions (the only change being that parts of these trials were run in parallel instead of sequentially - see fig 1 from [1]).
People getting sick after only receiving the first shot is fully expected.
The efficacy of the Biontech vaccine was only 54% after the first shot and only rose to 94% after the second.
And notice that it is not 100%.. so you would still expect some people to get infected after the second shot.. just much fewer cases.
People getting sick after only receiving the first shot is fully expected. The efficacy of the Biontech vaccine was only 54% after the first shot and only rose to 94% after the second. And notice that it is not 100%.. so you would still expect some people to get infected after the second shot.. just much fewer cases.
[1] https://www.nature.com/articles/s41586-020-2798-3